International Society for the Study of Women's Sexual Health

NEWS

General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH / ISSM Joint Meeting 2019
March 7-10, 2019   86 days left
Atlanta, GA, USA
Read more...

ISSWSH Fall Course 2019
November 14-16, 2019   338 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   450 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

Latest Tweets

Treatment with anticholinergics can improve sexual function in women with overactive bladder. #OAB #FSDhttps://t.co/4MSf0BaNhV ISSWSH
https://t.co/0VoTO5ivLH New trials regarding male contraceptive gel!!! Will men use it? Will it be effective? ISSWSH
Become a member of ISSWSH now and receive reduced rates on our meetings and courses! https://t.co/0IlRv5eBJ9 ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.